Observational studyScientific reports2026
CX3CR1-T280M polymorphism and end-stage renal disease development in chronic kidney disease.
Observational study in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD) is a major global health concern driven by hypertension and diabetes, with genetic factors playing a key role in its pathogenesis. CX3CR1, the sole known receptor for the chemokine fractalkine, and its polymorphisms T280M and V249I have been implicated in the progression of several chronic diseases. This prospective observational study investigates the role of the CX3CR1 T280M polymorphism in CKD progression to end-stage disease. We included 121 CKD patients with varying renal insufficiency severity. Patients were stratified by CX3CR1-T280M genotype: Group 1 wild-type (T/T, 71.9%) and Group 2 carriers of the mutated allele (T/M or M/M, 28.1%). The primary outcome was kidney replacement therapy (KRT) initiation over 18 years. Cox proportional hazards univariate analysis was used for survival assessment. The M allele for CX3CR1 is associated with higher baseline serum creatinine levels, consistent with previous cross-sectional studies. During follow-up, KRT was initiated in 26 patients (17.2% in Group 1, 32.3% in Group 2). Survival analysis showed a significant association between the CX3CR1-T280M polymorphism and CKD progression (HR 2.28, 95% CI: 1.04–4.98, p 0.039). This study confirms the role of the CX3CR1-T280M polymorphism in determining prognosis in CKD patients, particularly in predicting the risk of a critical outcome such as initiation of KRT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.